Published research on Fenbendazole
5 peer-reviewed publications on Fenbendazole in oncology research, clinical work first, then laboratory studies. Each entry reports what the authors stated; follow the link for the full paper.
- Case report
An 80-year-old woman with advanced non-small cell lung cancer on pembrolizumab developed severe liver injury after one month of self-administered fenbendazole, which resolved after discontinuation, and no tumour shrinkage was observed.
- In vivo
Fenbendazole showed moderate affinity for mammalian tubulin, was cytotoxic to human cancer cells at micromolar concentrations, inhibited glucose uptake and glycolytic enzymes, and blocked growth of human xenografts in mice when given orally.
- In vivo
Fenbendazole as a potential anticancer drug
Fenbendazole was toxic to EMT6 mouse mammary tumour cells in vitro, but maximally intensive regimens did not alter growth of EMT6 tumours in mice or increase the effects of radiation, and the authors reported no evidence that fenbendazole would have value in cancer therapy.
- In vivo
Unexpected antitumorigenic effect of fenbendazole when combined with supplementary vitamins
In SCID mice implanted with human lymphoma cells, neither fenbendazole nor supplementary vitamins alone altered tumour growth, whereas the combination of both significantly inhibited tumour growth.
- In vitro
Anti-cancer effects of fenbendazole on 5-fluorouracil-resistant colorectal cancer cells
Fenbendazole induced apoptosis and G2/M cell cycle arrest in both wild-type and 5-fluorouracil-resistant SNU-C5 colorectal cancer cells, and its activity in the resistant cells did not require p53.
Fenbendazole in the catalog (specifications, pack sizes, Certificate of Analysis)